Compare SPDR Gold Trust (GLD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Natera Inc. Common Stock — how do they compare? SPDR Gold Trust trades at $381 (market cap $141.50B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: SPDR Gold Trust is far larger — about 2.5× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 75 Days and Natera Inc. Common Stock for 0 Days on average.
| GLD | NTRA | |
|---|---|---|
Market Cap | $141.50B | $57.03B |
Volume | 5,707,251 | 1,131,157 |
52-Week High | $495.90 | $425.64 |
52-Week Low | $362.32 | $179.42 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, trades at $381.67, down 0.13% amid pressure from rising Treasury yields and a stronger U.S. dollar. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with prices testing key support levels near $380.
The outlook for GLD hinges on interest rate trends and macroeconomic uncertainty. While gold serves as a hedge against inflation and debt concerns, near-term headwinds from elevated yields and Fed policy uncertainty pose risks. A tactical buying opportunity may emerge if support holds, but sustained gains require a shift in monetary policy sentiment.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
